Edgar Filing: Sorrento Therapeutics, Inc. - Form 4

	erapeutics, Inc.										
Form 4 January 05	2015										
January 05, 2015									OMB APPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
Check th if no long subject to Section 1 Form 4 o Form 5 obligatio	ger 5 STATEM 16. 5 Filed pure 5 Section 17(1)	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section								Expires:January 31, 2005Estimated average burden hours per response0.5	
<i>See</i> Instruction 1(b). 30(h) of the Investment Company Act of 1940											
(Print or Type Responses)											
Ji Henry Symb			ymbol	Name and Therape			-	5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (N		Sorrento Therapeutics, Inc. [SRNE] 3. Date of Earliest Transaction					(Check	c all applicable)	
(Month/Day/Year)X_ Director C/O SORRENTO THERAPEUTICS, 12/31/2014X_ Officer (g below)						X Officer (give below)	te title 10% Owner below) sident and CEO				
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting 					
SAN DIEGO, CA 92121											
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ate, if	3. Transactio Code (Instr. 8)	4. Securit n(A) or Dis (Instr. 3, 4	sposed	l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D)	Price	(Instr. 3 and 4)		5.00	
Common Stock	12/31/2014			G	15,000	D	\$ 10.07	2,053,162	Ι	See Footnote	
Common Stock	01/02/2015			G	10,000	D	\$ 10.16	2,043,162	Ι	See Footnote (1)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: Sorrento Therapeutics, Inc. - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	Amor Unde Secur	tle and unt of rrlying rities :. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
Repo	rting O	wners		Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
1	Reporting Ow	vner Name / Address		Relationships							

		Director	10% Owner	Officer	Other
Ji Henry C/O SORRENTO THEI 6042 CORNERSTONE SAN DIEGO, CA 9212	Х		President and CEO		
Signatures					
/s/ Henry Ji	01/05/2015				
**Signature of	Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares are held in family trusts, of which Dr. Ji is a co-trustee with his wife.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Person